Medical World News® Inside the Practice: CancerNetwork® With Anthony W. Tolcher, MD, and Alexander I. Spira, MD, PhD, on Expand Access to Phase 1 Cancer Trials

Video

CancerNetwork® spoke with Anthony W. Tolcher, MD, and Alexander I. Spira MD, PhD, about NEXT Oncology partnering with the Phase 1 Trials Program at Virginia Cancer Specialists to give patients another chance at treatment.

For the latest installment of the Inside the Practice Segment of the Medical World News® broadcast, CancerNetwork® spoke with Anthony W. Tolcher, MD, co-founder of NEXT Oncology and a medical oncologist at Texas Oncology, as well as Alexander I. Spira, MD, PhD, director of Virginia Cancer Specialists Research Institute and the Phase I Trial Program, to discuss their new partnership and how this can positively affect patients who have run out of treatment options.

The aim of the partnership with NEXT and Phase 1 program was to make treatment more accessible in the community setting. As both programs were looking to expand, investigators from both organizations realized they needed more technology and accessibility to be successful.

Tolcher spoke about the importance of this partnership, stating how grateful patients are to have another chance at trying different treatment when others didn’t work. He also spoke about altruistic patients who want to receive treatment on clinical trial in the hopes that it could help others in the future. Tolcher continued stating how important it is that patients participate in trials in order to receive the best care possible and to help clinicians find the right treatment combinations.

Spira discussed how exciting it is to be partnering with NEXT Oncology in the hopes of expanding to more institutions around the country and around the world. Currently, he said they are working with clinicians in Spain to build a similar program. He mentions that the partnership will allow the Phase 1 program access to more clinical trials and in turn allow more of an opportunity to help patients.

This segment comes from the CancerNetwork® portion of the MJH Life Sciences™ Medical World News®, airing daily on all MJH Life Sciences™ channels.

Recent Videos
Patients who face smoking stigma, perceive a lack of insurance, or have other low-dose CT related concerns may benefit from blood testing for lung cancer.
The Together for Supportive Cancer Care coalition may advance the national conversation in ensuring comprehensive care for all patients with cancer.
Health care organizations have come together to form the Together for Supportive Cancer Care coalition to address gaps in supportive cancer care services.
Further optimizing a PROTAC that targets MDM2 may lead to human clinical trials among patients with cancer harboring p53 mutations.
Subsequent testing among patients in a prospective study may affirm the ability of cfDNA sequencing to detect cancers in those with Li-Fraumeni syndrome.
cfDNA sequencing may allow for more accessible, frequent, and sensitive testing compared with standard surveillance in Li-Fraumeni syndrome.
STX-478 showed efficacy in patients with advanced solid tumors regardless of whether they had kinase domain or helical PI3K mutations.
STX-478 may avoid adverse effects associated with prior PI3K inhibitors that lack selectivity for the mutated protein vs the wild-type protein.
Phase 1 data may show the possibility of rationally designing agents that can preferentially target PI3K mutations in solid tumors.